8-BuS-ATP derivatives as specific NTPDase1 inhibitors

British Journal of Pharmacology

Volumn 169, Issue 1, 2013, Pages 179-196

  Lecka, Joanna ^a   Gillerman, Irina ^b   Fausther, Michel ^a   Salem, Mabrouka ^a   Munkonda, Mercedes N ^a   Brosseau, Jean Philippe ^c   Cadot, Christine ^d   Martín Satué, Mireia ^a,e   D'Orléans Juste, Pedro ^c   Rousseau, Éric ^c   Poirier, Donald ^d   Künzli, Beat ^f   Fischer, Bilha ^b   Sévigny, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF BARCELONA   (Spain)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

adenine nucleotide analogue; ADP; ATP; ectoATPase; ectonucleotidase; inhibitors

Indexed keywords

8 BUTYLTHIO 2',3' ISOPROPYLIDENE ADENOSINE; 8 BUTYLTHIO 2',3' ISOPROPYLIDENE ADENOSINE BETA,GAMMA METHYLENE 5' TRIPHOSPHATE; 8 BUTYLTHIO 5' BETA,GAMMA METHYLENE ADENOSINE 5' TRIPHOSPHATE; 8 BUTYLTHIO BETA,GAMMA IMIDO ADENOSINE 5' TRIPHOSPHATE; 8 BUTYLTHIOADENOSINE; 8 BUTYLTHIOADENOSINE 5' DIPHOSPHATE; 8 BUTYLTHIOADENOSINE 5' MONOPHOSPHATE; 8 BUTYLTHIOADENOSINE 5' TRIPHOSPHATE DERIVATIVE; ENZYME INHIBITOR; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 2; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 3; NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 8; PHOSPHATASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; PLATELET AGGREGATION; RATS; SPECIES SPECIFICITY;

EID: 84876266707     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12135     Document Type: Article

References (74)

1. Atkinson B, Dwyer K, Enjyoji K, Robson SC, (2006). Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cells Mol Dis 36: 217-222.
2. Baqi Y, Atzler K, Kose M, Glanzel M, Muller CE, (2009). High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem 52: 3784-3793.
3. Baykov AA, Evtushenko OA, Avaeva SM, (1988). A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal Biochem 171: 266-270.
4. Belli SI, Goding JW, (1994). Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphodiesterase I and nucleotide pyrophosphatase activities. Eur J Biochem 226: 433-443.
5. Bigonnesse F, Lévesque SA, Kukulski F, Lecka J, Robson SC, Fernandes MJG, et al. (2004). Cloning and characterization of mouse nucleoside triphosphate diphosphohydrolase-8. Biochemistry 43: 5511-5519.
6. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232.
7. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
8. Braun N, Sévigny J, Mishra SK, Robson SC, Barth SW, Gerstberger R, et al. (2003). Expression of the ecto-ATPase NTPDase2 in the germinal zones of the developing and adult rat brain. Eur J Neurosci 17: 1355-1364.
9. Bultmann R, Wittenburg H, Pause B, Kurz G, Nickel P, Starke K, (1996). P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn Schmiedebergs Arch Pharmacol 354: 498-504.
10. Burnstock G, (2006a). Purinergic P2 receptors as targets for novel analgesics. Pharmacol Ther 110: 433-454.
11. Burnstock G, (2006b). Purinergic signalling. Br J Pharmacol 147 (Suppl. 1): S172-S181.
12. Burnstock G, (2007). Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87: 659-797.
13. Chen BC, Lee CM, Lin WW, (1996). Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Br J Pharmacol 119: 1628-1634.
14. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. (2006). The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 25: 4615-4627.
15. Cornish-Bowden A, (1974). A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137: 143-144.
16. Crack BE, Pollard CE, Beukers MW, Roberts SM, Hunt SF, Ingall AH, et al. (1995). Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol 114: 475-481.
17. Dahl RH, Pratley JN, (1967). The effects of magnesium on nucleoside phosphatase activity in frog skin. J Cell Biol 33: 411-418.
18. Deaglio S, Robson SC, (2011). Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 61: 301-332.
19. Dixon M, (1953). The determination of enzyme inhibitor constants. Biochem J 55: 170-171.
20. Dixon M, (1965). Graphical determination of equilibrium constants. Biochem J 94: 760-762.
21. Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Schulte Am Esch II J, et al. (1999). Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5: 1010-1017.
22. Erlinge D, Burnstock G, (2008). P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4: 1-20.
23. Fausther M, Lecka J, Kukulski F, Lévesque SA, Pelletier J, Zimmermann H, et al. (2007). Cloning, purification and identification of the liver canalicular ecto-ATPase as NTPDase8. Am J Physiol 292: G785-G795.
24. Fausther M, Pelletier J, Ribeiro CM, Sévigny J, Picher M, (2010). Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3. Am J Physiol Lung Cell Mol Physiol 298: L804-L818.
25. Feng L, Sun X, Csizmadia E, Han L, Bian S, Murakami T, et al. (2011). Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 13: 206-216.
26. Flick JT, Singh AK, Kizer J, Lazarchick J, (1991). Platelet dysfunction in Noonan's syndrome. A case with a platelet cyclooxygenase-like deficiency and chronic idiopathic thrombocytopenic purpura. Am J Clin Pathol 95: 739-742.
27. Gachet C, (2012). P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal 8: 609-619.
28. Gendron FP, Halbfinger E, Fischer B, Duval M, D'Orleans-Juste P, Beaudoin AR, (2000). Novel inhibitors of nucleoside triphosphate diphosphohydrolases: chemical synthesis and biochemical and pharmacological characterizations. J Med Chem 43: 2239-2247.
29. Gillerman I, Fischer B, (2010). An improved one-pot synthesis of nucleoside 5′-triphosphate analogues. Nucleosides Nucleotides Nucleic Acids 29: 245-256.
30. Goding JW, Grobben B, Slegers H, (2003). Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/ phosphodiesterase family. Biochim Biophys Acta 1638: 1-19.
31. Guckelberger O, Sun XF, Sévigny J, Imai M, Kaczmarek E, Enjyoji K, et al. (2004). Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 91: 576-586.
32. Halbfinger E, Major DT, Ritzmann M, Ubl J, Reiser G, Boyer JL, et al. (1999). Molecular recognition of modified adenine nucleotides by the P2Y(1)-receptor. 1. A synthetic, biochemical, and NMR approach. J Med Chem 42: 5325-5337.
33. Hechler B, Cattaneo M, Gachet C, (2005). The P2 receptors in platelet function. Semin Thromb Hemost 31: 150-161.
34. Hourani SM, (1996). Purinoceptors and platelet aggregation. J Auton Pharmacol 16: 349-352.
35. Iqbal J, Vollmayer P, Braun N, Zimmermann H, Muller CE, (2005). A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signal 1: 349-358.
36. Jinhua P, Goding JW, Nakamura H, Sano K, (1997). Molecular cloning and chromosomal localization of PD-I-beta (PDNP3), a new member of the human phosphodiesterase I genes. Genomics 45: 412-415.
37. Kaczmarek E, Koziak K, Sévigny J, Siegel JB, Anrather J, Beaudoin AR, et al. (1996). Identification and characterization of CD39 vascular ATP diphosphohydrolase. J Biol Chem 271: 33116-33122.
38. Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D'Orléans-Juste P, et al. (2010). NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 85: 204-213.
39. Knowles AF, Chiang WC, (2003). Enzymatic and transcriptional regulation of human ecto-ATPase/E-NTPDase 2. Arch Biochem Biophys 418: 217-227.
40. Kukulski F, Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF, et al. (2005). Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 1: 193-204.
41. Kukulski F, Bahrami F, Ben Yebdri F, Lecka J, Martín-Satué M, Lévesque SA, et al. (2011a). NTPDase1 controls IL-8 production by buman neutrophils. J Immunol 187: 644-653.
42. Kukulski F, Lévesque SA, Sévigny J, (2011b). Impact of ectoenzymes on P2 and P1 receptor signaling. Adv Pharmacol 61: 263-299.
43. Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Sévigny J, (2007). Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. Br J Pharmacol 152: 141-150.
44. Li L, Jia ZH, Chen C, Wei C, Han JK, Wu YL, et al. (2011). Physiological significance of P2X receptor-mediated vasoconstriction in five different types of arteries in rats. Purinergic Signal 7: 221-229.
45. Ludwig J, (1981). A new route to nucleoside 5′-triphosphates. Acta Biochim Biophys Acad Sci Hung 16: 131-133.
46. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, et al. (2009). Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 15: 6348-6357.
47. Marcus AJ, Safier LB, Hajjar KA, Ullman HL, Islam N, Broekman MJ, et al. (1991). Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest 88: 1690-1696.
48. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, et al. (2003). Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 305: 9-16.
49. Mareeva TB, Sokovnina Ia M, Votrin II, (1987). The role of adenine nucleotides in the functional activity of platelets in hemophilia A. Vop Med Khim 33: 100-104.
50. Moncrieffe H, Nistala K, Kamhieh Y, Evans J, Eddaoudi A, Eaton S, et al. (2010). High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol 185: 134-143.
51. Müller CE, Iqbal J, Bagi Y, Zimmermann H, Rollich A, Stephan H, (2006). Polyoxometalates-a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. Bioorg Med Chem Lett 16: 5943-5947.
52. Munkonda MN, Kauffenstein G, Kukulski F, Lévesque SA, Legendre C, Pelletier J, et al. (2007). Inhibition of human and mouse plasma membrane bound NTPDases by P2 receptor antagonists. Biochem Pharmacol 74: 1524-1534.
53. Munkonda MN, Pelletier J, Ivanenkov VV, Fausther M, Tremblay A, Kunzli B, et al. (2009). Characterization of a monoclonal antibody as the first specific inhibitor of human NTP diphosphohydrolase-3: partial characterization of the inhibitory epitope and potential applications. FEBS J 276: 479-496.
54. Oliveira CB, Da Silva AS, Vargas LB, Bitencourt PE, Souza VC, Costa MM, et al. (2011). Activities of adenine nucleotide and nucleoside degradation enzymes in platelets of rats infected by Trypanosoma evansi. Vet Parasitol 178: 9-14.
55. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC, (2003). Ecto 5′-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278: 13468-13479.
56. Robson SC, Sévigny J, Zimmermann H, (2006). The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2: 409-430.
57. Sévigny J, Robson SC, Waelkens E, Csizmadia E, Smith RN, Lemmens R, (2000). Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase. J Biol Chem 275: 5640-5647.
58. Sévigny J, Sundberg C, Braun N, Guckelberger O, Csizmadia E, Qawi I, et al. (2002). Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99: 2801-2809.
59. Smith TM, Kirley TL, (1998). Cloning, sequencing, and expression of a human brain ecto-apyrase related to both the ecto-ATPases and CD39 ecto-apyrases. Biochim Biophys Acta 1386: 65-78.
60. Stafford NP, Pink AE, White AE, Glenn JR, Heptinstall S, (2003). Mechanisms involved in adenosine triphosphate-induced platelet aggregation in whole blood. Arterioscler Thromb Vasc Biol 23: 1928-1933.
61. Stojilkovic SS, Koshimizu T, (2001). Signaling by extracellular nucleotides in anterior pituitary cells. Trends Endocrin Met 12: 218-225.
62. Straub A, Krajewski S, Hohmann JD, Westein E, Jia F, Bassler N, et al. (2011). Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol 31: 1607-1616.
63. Vekaria RM, Shirley DG, Sévigny J, Unwin RJ, (2006). Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 290: F550-F560.
64. Vollmayer P, Clair T, Goding JW, Sano K, Servos J, Zimmermann H, (2003). Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/ phosphodiesterases. Eur J Biochem 270: 2971-2978.
65. Waehre T, Damas JK, Pedersen TM, Gullestad L, Yndestad A, Andreassen AK, et al. (2006). Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 4: 2140-2147.
66. Wall MJ, Chen J, Meegalla S, Ballentine SK, Wilson KJ, DesJarlais RL, et al. (2008). Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors. Bioorg Med Chem Lett 18: 2097-2102.
67. Walsh PN, Mills DC, Pareti FI, Stewart GJ, Macfarlane DE, Johnson MM, et al. (1975). Hereditary giant platelet syndrome. Absence of collagen-induced coagulant activity and deficiency of factor-XI binding to platelets. Br J Haematol 29: 639-655.
68. Wittenburg H, Bultmann R, Pause B, Ganter C, Kurz G, Starke K, (1996). P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue. Naunyn Schmiedebergs Arch Pharmacol 354: 491-497.
69. Yegutkin GG, Helenius M, Kaczmarek E, Burns N, Jalkanen S, Stenmark K, et al. (2011). Chronic hypoxia impairs extracellular nucleotide metabolism and barrier function in pulmonary artery vasa vasorum endothelial cells. Angiogenesis 14: 503-513.
70. Yegutkin GG, Wieringa B, Robson SC, Jalkanen S, (2012). Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 Activities. FASEB J 26: 3875-3883.
71. Zimmermann H, (2001). Ectonucleotidases: some recent developments and note on nomenclature. Drug Develop Res 52: 44-56.
72. Zimmermann H, (2006). Nucleotide signaling in nervous system development. Pflugers Arch 452: 573-588.
73. Zimmermann H, Zebisch M, Strater N, (2012). Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8: 437-502.
74. Zylka MJ, (2011). Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 17: 188-196.